Notes
The study was funded by Novartis Pharma AG, Switzerland.
Ranibizumab and vPDT evaluation in Myopic CNV
Verteporfin in Photodynamic Therapy
Reference
Claxton L, et al. Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs and Aging : 10 Oct 2014. Available from: URL: http://doi.org/10.1007/s40266-014-0216-y
Rights and permissions
About this article
Cite this article
Ranibizumab preferred option in myopic CNV. PharmacoEcon Outcomes News 715, 25 (2014). https://doi.org/10.1007/s40274-014-1683-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1683-4